Patents by Inventor Sridhar Krishna Rabindran

Sridhar Krishna Rabindran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR TREATING GEFITINIB RESISTANT CANCER
    Publication number: 20230226039
    Abstract: The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/ or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.
    Type: Application
    Filed: August 17, 2022
    Publication date: July 20, 2023
    Inventors: Daniel A. Haber, Daphne Winifred Bell, Jeffrey E. Settleman, Raffaella Sordella, Nadia G. Godin-Heymann, Eunice L. Kwak, Sridhar Krishna Rabindran
  • Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272
    Publication number: 20230201155
    Abstract: A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described.
    Type: Application
    Filed: July 22, 2022
    Publication date: June 29, 2023
    Inventors: Laurence Moore, Charles Michael Zacharchuk, Sridhar Krishna Rabindran
  • Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272
    Publication number: 20220354820
    Abstract: A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described.
    Type: Application
    Filed: December 10, 2021
    Publication date: November 10, 2022
    Inventors: Laurence Moore, Charles Michael Zacharchuk, Sridhar Krishna Rabindran
  • Method for treating gefitinib resistant cancer
    Patent number: 10603314
    Abstract: The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.
    Type: Grant
    Filed: February 2, 2006
    Date of Patent: March 31, 2020
    Assignees: The General Hospital Corporation, Wyeth LLC
    Inventors: Daniel A. Haber, Daphne Winifred Bell, Jeffrey E. Settleman, Raffaella Sordella, Nadia G. Godin-Heymann, Eunice L. Kwak, Sridhar Krishna Rabindran
  • Method for treating gefitinib resistant cancer
    Patent number: 10596162
    Abstract: The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB 569, HKI-272 and HKI-357.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: March 24, 2020
    Assignees: Wyeth LLC, The General Hospital Corporation
    Inventors: Daniel A. Haber, Daphne Winifred Bell, Jeffrey E. Settleman, Raffaella Sordella, Nadia G. Godin-Heymann, Eunice L. Kwak, Sridhar Krishna Rabindran
  • METHOD FOR TREATING GEFITINIB RESISTANT CANCER
    Publication number: 20160310482
    Abstract: The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB 569, HKI-272 and HKI-357.
    Type: Application
    Filed: July 11, 2016
    Publication date: October 27, 2016
    Inventors: Daniel A. Haber, Daphne Winifred Bell, Jeffrey E. Settleman, Raffaella Sordella, Nadia G. Godin-Heymann, Eunice L. Kwak, Sridhar Krishna Rabindran
  • Protein tyrosine kinase enzyme inhibitors
    Patent number: 7982043
    Abstract: This invention provides compounds of formula 1, having the structure wherein R1, R2, R3, R4, and R5 are described within the specification.
    Type: Grant
    Filed: June 10, 2008
    Date of Patent: July 19, 2011
    Assignee: Wyeth LLC
    Inventors: Allan Wissner, Sridhar Krishna Rabindran, Hwei-Ru Tsou
  • PROTEIN TYROSINE KINASE ENZYME INHIBITORS
    Publication number: 20080319011
    Abstract: This invention provides compounds of formula 1, having the structure wherein R1, R2, R3, R4, and R5 are described within the specification.
    Type: Application
    Filed: June 10, 2008
    Publication date: December 25, 2008
    Applicant: Wyeth
    Inventors: Allan Wissner, Sridhar Krishna Rabindran, Hwei-Ru Tsou
  • Actinomadura Chromoprotein, Apoprotein and Gene Cluster
    Publication number: 20080274959
    Abstract: The present invention provides a chromoprotein produced by Actinomadura sp. 21G792, as well as amino acid and nucleic acid sequences of the apoprotein component of the chromoprotein and of components of the biosynthetic pathway for the chromophore. The present invention is useful for developing pharmaceutical and treating diseases such as cancer or bacterial infections.
    Type: Application
    Filed: December 16, 2005
    Publication date: November 6, 2008
    Applicant: Wyeth
    Inventors: Bradley A. Haltli, Haiyin He, Ying Huang, Sridhar Krishna Rabindran, Jiang Wu, Min He
  • Protein tyrosine kinase enzyme inhibitors
    Patent number: 7399865
    Abstract: This invention provides compounds of formula 1, having the structure wherein R1, R2, R3, R4, and R5 are described within the specification.
    Type: Grant
    Filed: September 10, 2004
    Date of Patent: July 15, 2008
    Assignee: Wyeth
    Inventors: Allan Wissner, Sridhar Krishna Rabindran, Hwei-Ru Tsou
  • Reversal of multidrug resistance in human colon carcinoma cells
    Patent number: 6878737
    Abstract: The present invention describes the use of fumitremorgin A, B and C and a series of diketopiperazines of Formula (I) to resensitize multidrug resistant (MDR) cancer cells to the cytotoxic effects of chemotherapeutic drugs.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: April 12, 2005
    Assignee: Wyeth Holdings Corporation
    Inventors: Sridhar Krishna Rabindran, Haiyin He, Lee Martin Greenberger
  • Reversal of multidrug resistance in human colon carcinoma cells
    Publication number: 20030083230
    Abstract: The present invention describes the use of fumitremorgin A, B and C and a series of diketopiperazines of Formula (I) to resensitize multidrug resistant (MDR) cancer cells to the cytotoxic effects of chemotherapeutic drugs.
    Type: Application
    Filed: February 28, 2002
    Publication date: May 1, 2003
    Applicant: American Cyanamid Company
    Inventors: Sridhar Krishna Rabindran, Haiyin He, Lee Martin Greenberger
  • Reversal of multidrug resistance in human colon carcinoma cells
    Publication number: 20020156015
    Abstract: The present invention describes the use of fumitremorgin A, B and C and a series of diketopiperazines of Formula (I) to resensitize multidrug resistant (MDR) cancer cells to the cytotoxic effects of chemotherapeutic drugs.
    Type: Application
    Filed: February 28, 2002
    Publication date: October 24, 2002
    Applicant: American Cyanamid Company
    Inventors: Sridhar Krishna Rabindran, Haiyin He, Maya Prakash Singh, Lee Martin Greenberger
  • Reversal of multidrug resistance in human colon carcinoma cells
    Patent number: 6372775
    Abstract: The present invention describes the use of fumitremorgin A, B and C and a series of diketopiperazines of Formula (I) to resensitize multidrug resistant (MDR) cancer cells to the cytotoxic effects of chemotherapeutic drugs.
    Type: Grant
    Filed: May 27, 1999
    Date of Patent: April 16, 2002
    Assignee: American Cyanamid Company
    Inventors: Sridhar Krishna Rabindran, Haiyin He, Lee Martin Greenberger